本帖最后由 maicon08 于 2023-4-28 15:12 编辑 7 A+ O e# q4 I1 Q% x) C
( a( X2 }; O/ t: Q- b一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。1 z, T- h* a" {* t7 d; B. ?# C
1 ^0 w1 z1 O) l3 B( k( e
https://www.163.com/dy/article/I3BTTPRD053438SI.html7 K* d2 B8 d1 [$ ^5 l1 h
! S0 C5 F2 L2 t' P' j
: Q9 W$ N5 ~- z# Z在研疗法-免疫治疗
/ u1 y( w# _# {% g, SDevelopmental Therapeutics—Immunotherapy
+ y7 M# |/ A* D7 z" h 6 X7 R r# ? ` ^3 U B2 C! `3 X
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
, o' y/ F, u: i; z9 D& E) _
在研疗法-分子靶向药物和肿瘤生物学
( B' |: O% T0 P Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 1 {. `. f0 x0 |7 R+ ?/ h6 b- K, Y
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
& t& j, W0 ~3 \2 r/ {* S( P
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
) P7 g" w8 T1 f% t5 z
胃肠道肿瘤-结直肠癌和肛门癌
9 D; S! J7 N" l2 k5 N# D9 h) t0 ^ Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 0 t* @5 a$ s' r1 Y1 L9 Z
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
0 _. ]. \1 B7 y% w/ {摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
; i( p- x7 ]; L) j+ t) h, b5 P
妇科肿瘤 Gynecologic Cancer
# o; S3 w% a7 s9 T% y3 ?摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 7 V" D7 C3 s& I, @8 M# u
头颈肿瘤
* {$ i% a- ]2 e Head and Neck Cancer
8 C* x( f& R4 h$ p9 L摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 + S6 H5 A' V; i. Q$ }. D" r+ j
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
% z$ _2 o. E) {7 ]+ x, j% }# |! B
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
0 O. o! e/ A9 y9 m/ \9 D1 U1 Z7 g% q# ~& S
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ! p) c) ~$ o; v; N, [
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
% } j% u, o0 ^0 ^2 r$ r
血液系统恶性肿瘤-浆细胞疾病
+ g% ^8 e6 S$ ~" P Hematologic Malignancies—Plasma Cell Dyscrasia . I' Q8 K: W' Z. o
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 1 M9 c5 L6 T$ v* C( P w
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤/ ^& E! r: i7 B" G
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers 8 w3 ?; y, N ~( f, _/ U4 L9 I
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
8 D' q* I% N3 n3 c8 F) @
肺癌-转移性非小细胞肺癌
: H `5 J& k% h4 P4 _ Lung Cancer—Non-Small Cell Metastatic
9 I) u, g8 j" J摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 2 t& a4 b9 v1 {* y1 [2 j
, @! ^- k/ E5 R; G5 `+ b0 e摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
& B2 s \! ?9 t- h( ^: n
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
+ S* {) z# `0 _0 s
黑色素瘤/皮肤癌
3 k9 O8 [. r- d$ z; F9 d Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 5 P0 F9 {, N8 E
快速摘要报告3 b z. m+ m9 R. i+ @8 w6 W4 V$ B
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
8 x) p! o. Z& h8 `, J
临床科学研讨会/ @1 q7 |8 y0 U. w+ ^2 x Z
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 % z* I3 J7 m" c. X
& t) |, W. z: e9 J" C3 @
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
